Abstract:Accurate prediction of cancer drug response (CDR) is a longstanding challenge in modern oncology that underpins personalized treatment. Current computational methods implement CDR prediction by modeling responses between entire drugs and cell lines, without the consideration that response outcomes may primarily attribute to a few finer-level 'subcomponents', such as privileged substructures of the drug or gene signatures of the cancer cell, thus producing predictions that are hard to explain. Herein, we present SubCDR, a subcomponent-guided deep learning method for interpretable CDR prediction, to recognize the most relevant subcomponents driving response outcomes. Technically, SubCDR is built upon a line of deep neural networks that enables a set of functional subcomponents to be extracted from each drug and cell line profile, and breaks the CDR prediction down to identifying pairwise interactions between subcomponents. Such a subcomponent interaction form can offer a traceable path to explicitly indicate which subcomponents contribute more to the response outcome. We verify the superiority of SubCDR over state-of-the-art CDR prediction methods through extensive computational experiments on the GDSC dataset. Crucially, we found many predicted cases that demonstrate the strength of SubCDR in finding the key subcomponents driving responses and exploiting these subcomponents to discover new therapeutic drugs. These results suggest that SubCDR will be highly useful for biomedical researchers, particularly in anti-cancer drug design. The ability to predict the response of a cancer patient to a therapeutic drug is a major goal in modern oncology. Computational methods have led to significant progress in predicting cancer drug response (CDR), but they ignore that response outcomes may be highly associated with specific 'subcomponents', such as privileged substructures of drugs or gene signatures of cancer cells. To understand the effect of subcomponents in CDR prediction, we present a subcomponents-guided deep learning method, named SubCDR. SubCDR is based on multiple deep neural networks capable of extracting functional subcomponents from the drug SMILES and cell line transcriptome, and decomposing the response prediction between the drug and cell line into identifying pairwise interactions between their respective subcomponents. With this interaction form, we can obtain a traceable path to explicitly identify subcomponents contributing significantly to the response outcome. We validate our method on the GDSC dataset and demonstrate improvements over the state-of-the-art CDR prediction methods. Furthermore, we show the strength of SubCDR in interpreting the CDRs and discovering new drugs with sensitive responses from the view of subcomponent interaction.

scDR: Predicting Drug Response at Single-Cell Resolution

Scrank Infers Drug-Responsive Cell Types from Untreated Scrna-Seq Data Using a Target-Perturbed Gene Regulatory Network

scDrug+: predicting drug-responses using single-cell transcriptomics and molecular structure

Integration of pan-cancer cell line and single-cell transcriptomic profiles enables inference of therapeutic vulnerabilities in heterogeneous tumors

scDrugAtlas: an integrative single-cell drug response atlas for unraveling tumor heterogeneity in therapeutic efficacy

scPharm: identifying pharmacological subpopulations of single cells for precision medicine in cancers

DrugReSC: targeting disease-critical cell subpopulations with single-cell transcriptomic data for drug repurposing in cancer

Enabling Single‐Cell Drug Response Annotations from Bulk RNA‐Seq Using SCAD

Single-Cell Techniques and Deep Learning in Predicting Drug Response.

Decoding Drug Response with Structurized Gridding Map-based Cell Representation.

DROEG: a method for cancer drug response prediction based on omics and essential genes integration

A novel heterogeneous network-based method for drug response prediction in cancer cell lines

CeDR Atlas: a knowledgebase of cellular drug response

TransCDR: a deep learning model for enhancing the generalizability of cancer drug response prediction through transfer learning and multimodal data fusion for drug representation

Estimating the impact of single-cell RNA sequencing of human tissues on drug target validation.

A subcomponent-guided deep learning method for interpretable cancer drug response prediction

Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines

Deep Transfer Learning of Drug Responses by Integrating Bulk and Single-cell RNA-seq data

DRN-CDR: A cancer drug response prediction model using multi-omics and drug features

DDRS: Detection of drug response SNPs specifically in patients receiving drug treatment

Predicting patient treatment response and resistance via single-cell transcriptomics of their tumors.